Outsourcing

Articles

Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.

Lonza and Bioqube Ventures Form Agreement for Future Development and Manufacture of Biologics and Small Molecules

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp to Build mRNA Vaccine Manufacturing Capacity

Hovione will invest $170 million in new capacity and capabilities in Portugal, Ireland, and New Jersey

Hovione Expands Capacity Globally

Meg Rivers is the former senior editor for 

Navigating a complex global regulatory landscape involves upfront research into the expectations of the different regulatory bodies, thorough documentation of every step of the API manufacturing process, and good communication. 

Global Regulatory Approach to API Manufacturing

Between dosage form versatility, product stability, lack of storage restrictions or need to refrigerate, and an easier means of purification, small-molecule APIs present an appealing market niche.

API Development and Manufacturing: Advantages of Working with Small Molecules

Quotient Sciences is investing £6.3 million ($8.68 million) into their drug substance manufacturing capabilities.

Quotient Sciences Makes Multi-Million Dollar Investment to Expand Drug Substance Manufacturing Facility

Curia plans to expand the site’s commercial capabilities with this move.

Curia to Invest $35 Million in Expansions Into Rensselaer, NY Facility

Biotage’s new facility in Cardiff, UK, will produce lipids using large-scale flash purification.

Biotage Expands Lipid Capacity with New Facility

Almac Sciences has signed a manufacturing agreement with Pila Pharma for the production of the API XEN-D0501.

Almac Group and Pila Pharma Sign Manufacturing Agreement 

UltraBurst has a high disintegration speed, which is for all market segments, from prescriptions to nutraceuticals.

Contract Manufacturing, Drug Substance, API